These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 23097455)

  • 1. Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein.
    Keck Z; Wang W; Wang Y; Lau P; Carlsen TH; Prentoe J; Xia J; Patel AH; Bukh J; Foung SK
    J Virol; 2013 Jan; 87(1):37-51. PubMed ID: 23097455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.
    Keck ZY; Girard-Blanc C; Wang W; Lau P; Zuiani A; Rey FA; Krey T; Diamond MS; Foung SK
    J Virol; 2016 Jan; 90(6):3112-22. PubMed ID: 26739044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423.
    Keck ZY; Angus AG; Wang W; Lau P; Wang Y; Gatherer D; Patel AH; Foung SK
    PLoS Pathog; 2014 Aug; 10(8):e1004297. PubMed ID: 25122476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.
    Keck ZY; Xia J; Wang Y; Wang W; Krey T; Prentoe J; Carlsen T; Li AY; Patel AH; Lemon SM; Bukh J; Rey FA; Foung SK
    PLoS Pathog; 2012; 8(4):e1002653. PubMed ID: 22511875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.
    Costin JM; Zaitseva E; Kahle KM; Nicholson CO; Rowe DK; Graham AS; Bazzone LE; Hogancamp G; Figueroa Sierra M; Fong RH; Yang ST; Lin L; Robinson JE; Doranz BJ; Chernomordik LV; Michael SF; Schieffelin JS; Isern S
    J Virol; 2013 Jan; 87(1):52-66. PubMed ID: 23077306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.
    Keck ZY; Pierce BG; Lau P; Lu J; Wang Y; Underwood A; Bull RA; Prentoe J; Velázquez-Moctezuma R; Walker MR; Luciani F; Guest JD; Fauvelle C; Baumert TF; Bukh J; Lloyd AR; Foung SKH
    PLoS Pathog; 2019 May; 15(5):e1007772. PubMed ID: 31100098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2.
    Keck ZY; Li TK; Xia J; Bartosch B; Cosset FL; Dubuisson J; Foung SK
    J Virol; 2005 Nov; 79(21):13199-208. PubMed ID: 16227243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
    Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
    J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.
    Pierce BG; Keck ZY; Wang R; Lau P; Garagusi K; Elkholy K; Toth EA; Urbanowicz RA; Guest JD; Agnihotri P; Kerzic MC; Marin A; Andrianov AK; Ball JK; Mariuzza RA; Fuerst TR; Foung SKH
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32878891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.
    Keck ZY; Saha A; Xia J; Wang Y; Lau P; Krey T; Rey FA; Foung SK
    J Virol; 2011 Oct; 85(20):10451-63. PubMed ID: 21813602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.
    Hadlock KG; Lanford RE; Perkins S; Rowe J; Yang Q; Levy S; Pileri P; Abrignani S; Foung SK
    J Virol; 2000 Nov; 74(22):10407-16. PubMed ID: 11044085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody.
    Li Y; Pierce BG; Wang Q; Keck ZY; Fuerst TR; Foung SK; Mariuzza RA
    J Biol Chem; 2015 Apr; 290(16):10117-25. PubMed ID: 25737449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
    Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
    J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions.
    Keck ZY; Xia J; Cai Z; Li TK; Owsianka AM; Patel AH; Luo G; Foung SK
    J Virol; 2007 Jan; 81(2):1043-7. PubMed ID: 17079294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference.
    Sautto G; Mancini N; Diotti RA; Solforosi L; Clementi M; Burioni R
    Antiviral Res; 2012 Oct; 96(1):82-9. PubMed ID: 22898087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein.
    Vieyres G; Dubuisson J; Patel AH
    J Gen Virol; 2011 Mar; 92(Pt 3):494-506. PubMed ID: 21084495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions.
    Keck ZY; Op De Beeck A; Hadlock KG; Xia J; Li TK; Dubuisson J; Foung SK
    J Virol; 2004 Sep; 78(17):9224-32. PubMed ID: 15308717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.
    Carlsen TH; Pedersen J; Prentoe JC; Giang E; Keck ZY; Mikkelsen LS; Law M; Foung SK; Bukh J
    Hepatology; 2014 Nov; 60(5):1551-62. PubMed ID: 25043937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.